# ERRα-KDM5C restrains STING enhancer activity to modulate type I interferon signaling in breast cancer progression

**Authors:** Zu-Hui Xu, Jie Chen, Ying He, Cheng Lei, Xiao-Ling Wang, De-Fa Huang, Zheng-Zhe Li, Hui Zhou, Mei-Yan Wang, Cheng-Gui Song, Juan Lin, Wen Liu, Xiao-Nan Wu, Wen-Juan Zhang

PMC · DOI: 10.1038/s41419-026-08499-2 · Cell Death & Disease · 2026-02-18

## TL;DR

This study shows how the ERRα-KDM5C complex controls STING activity to influence breast cancer growth through interferon signaling.

## Contribution

The study reveals a novel regulatory mechanism where ERRα-KDM5C suppresses STING enhancer activity to modulate interferon signaling in breast cancer.

## Key findings

- ERRα and KDM5C co-occupy enhancers, including the STING locus, to regulate enhancer activity.
- ERRα depletion activates STING signaling, increasing interferon and ISG expression.
- ERRα suppression reduces breast tumor growth via STING signaling activation.

## Abstract

Regulation of enhancer activity plays a pivotal role in governing gene expression and cellular behaviors. However, the precise mechanisms underlying dynamic control of active enhancers remain incompletely defined. Here, we demonstrate that the nuclear receptor estrogen-related receptor α (ERRα) forms a functional complex with the H3K4me3-specific demethylase KDM5C to co-occupy a large set of active enhancers, including the locus of STING. In breast cancer cells, ERRα depletion induces STING enhancer hyperactivation, evidenced by H3K4me3 deposition, decreased H3K4me1, and increased enhancer RNA (eRNA) transcription. Accordingly, depletion of ERRα leads to further activation of STING gene transcription and TBK1-IRF3 pathway, accompanied by increased type I interferon (IFN) and IFN-stimulated gene (ISG) expression, as confirmed by transcriptomic analysis. Notably, depleting ERRα markedly attenuates breast tumor cell growth in vitro and in vivo, and our in vitro evidence indicates this occurs in part through activating STING signaling. These findings establish that the ERRα-KDM5C serves as a critical checkpoint for STING enhancer activity, revealing a regulatory mechanism of STING enhancer activity in breast tumor progression.

ERRα interacts with KDM5C to co-occupy active enhancers, including the locus of STING.ERRα depletion induces STING enhancer hyperactivation through KDM5C displacement and H3K4me3 deposition.STING-TBK1-IRF3 signaling activation mediates enhanced type I IFN/ISG expression upon ERRα depletion.ERRα contributes to breast tumor cell growth in vitro and in vivo, and our in vitro evidence indicates this occurs in part through suppression of STING signaling.

ERRα interacts with KDM5C to co-occupy active enhancers, including the locus of STING.

ERRα depletion induces STING enhancer hyperactivation through KDM5C displacement and H3K4me3 deposition.

STING-TBK1-IRF3 signaling activation mediates enhanced type I IFN/ISG expression upon ERRα depletion.

ERRα contributes to breast tumor cell growth in vitro and in vivo, and our in vitro evidence indicates this occurs in part through suppression of STING signaling.

## Linked entities

- **Genes:** ESRRA (estrogen related receptor alpha) [NCBI Gene 2101], KDM5C (lysine demethylase 5C) [NCBI Gene 8242], STING1 (stimulator of interferon response cGAMP interactor 1) [NCBI Gene 340061], TBK1 (TANK binding kinase 1) [NCBI Gene 29110], IRF3 (interferon regulatory factor 3) [NCBI Gene 3661]
- **Diseases:** breast cancer (MONDO:0004989)

## Full-text entities

- **Genes:** KDM5C (lysine demethylase 5C) [NCBI Gene 8242] {aka DXS1272E, JARID1C, MRX13, MRXJ, MRXS16, MRXSCJ}, IFIH1 (interferon induced with helicase C domain 1) [NCBI Gene 64135] {aka AGS7, Hlcd, IDDM19, IMD95, MDA-5, MDA5}, RIGI (RNA sensor RIG-I) [NCBI Gene 23586] {aka DDX58, RIG-I, RIG1, RLR-1, SGMRT2}, Tbk1 (TANK-binding kinase 1) [NCBI Gene 56480] {aka 1200008B05Rik}, EP300 (EP300 lysine acetyltransferase) [NCBI Gene 2033] {aka KAT3B, MKHK2, RSTS2, p300}, ESRRA (estrogen related receptor alpha) [NCBI Gene 2101] {aka ERR1, ERRa, ERRalpha, ESRL1, NR3B1}, TBK1 (TANK binding kinase 1) [NCBI Gene 29110] {aka AIARV, FTDALS4, IIAE8, NAK, T2K}, Kdm5c (lysine demethylase 5C) [NCBI Gene 20591] {aka D930009K15Rik, Jarid1c, Smcx, mKIAA0234}, Sting1 (stimulator of interferon response cGAMP interactor 1) [NCBI Gene 72512] {aka 2610307O08Rik, ERIS, MPYS, Mita, STING, STING-beta}, MAVS (mitochondrial antiviral signaling protein) [NCBI Gene 57506] {aka CARDIF, IPS-1, IPS1, VISA}, KDM5A (lysine demethylase 5A) [NCBI Gene 5927] {aka NEDEHC, RBBP-2, RBBP2, RBP2}, Actb (actin, beta) [NCBI Gene 11461] {aka Actx, E430023M04Rik, beta-actin}, KDM5B (lysine demethylase 5B) [NCBI Gene 10765] {aka CT31, JARID1B, MRT65, PLU-1, PLU1, PPP1R98}, Esrra (estrogen related receptor, alpha) [NCBI Gene 26379] {aka ERRalpha, Err1, Estrra, Nr3b1}, MED1 (mediator complex subunit 1) [NCBI Gene 5469] {aka CRSP1, CRSP200, DRIP205, DRIP230, PBP, PPARBP}, STING1 (stimulator of interferon response cGAMP interactor 1) [NCBI Gene 340061] {aka ERIS, MITA, MPYS, NET23, SAVI, STING}, TRBV20OR9-2 (T cell receptor beta variable 20/OR9-2 (non-functional)) [NCBI Gene 6962] {aka CDR3, TCRBV20S2, TCRBV2O, TCRBV2S2O}, CCL5 (C-C motif chemokine ligand 5) [NCBI Gene 6352] {aka D17S136E, RANTES, SCYA5, SIS-delta, SISd, TCP228}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, CREBBP (CREB binding lysine acetyltransferase) [NCBI Gene 1387] {aka CBP, KAT3A, MKHK1, RSTS, RSTS1}, IRF3 (interferon regulatory factor 3) [NCBI Gene 3661] {aka IIAE7}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, APEX1 (apurinic/apyrimidinic endodeoxyribonuclease 1) [NCBI Gene 328] {aka APE, APE1, APEN, APEX, APX, HAP1}, IFIT1 (interferon induced protein with tetratricopeptide repeats 1) [NCBI Gene 3434] {aka C56, G10P1, IFI-56, IFI-56K, IFI56, IFIT-1}, CGAS (cyclic GMP-AMP synthase) [NCBI Gene 115004] {aka C6orf150, D4, MB21D1, h-cGAS}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, OASL (2'-5'-oligoadenylate synthetase like) [NCBI Gene 8638] {aka OASL1, OASLd, TRIP-14, TRIP14, p59 OASL, p59-OASL}, IFNB1 (interferon beta 1) [NCBI Gene 3456] {aka IFB, IFF, IFN-beta, IFNB}, Irf3 (interferon regulatory factor 3) [NCBI Gene 54131] {aka C920001K05Rik, IRF-3}, BRCA1 (BRCA1 DNA repair associated) [NCBI Gene 672] {aka BRCAI, BRCC1, BROVCA1, FANCS, IRIS, PNCA4}, ESR1 (estrogen receptor 1) [NCBI Gene 2099] {aka ER, ESR, ESRA, ESTRR, Era, NR3A1}, IFNA1 (interferon alpha 1) [NCBI Gene 3439] {aka IFL, IFN, IFN-ALPHA, IFN-alphaD, IFNA13, IFNA@}
- **Diseases:** inflammation (MESH:D007249), prostate cancer (MESH:D011471), pancreatic cancer (MESH:D010190), Cancer (MESH:D009369), bleeding (MESH:D006470), papillary thyroid carcinoma (MESH:D000077273), tumorigenesis (MESH:D063646), type I (MESH:D006969), acute myeloid leukemia (MESH:D015470), cervical, cholangiocarcinoma (MESH:D002575), colon cancer (MESH:D015179), cytotoxicity (MESH:D064420), breast cancer (MESH:D001943), ovarian cancer (MESH:D010051), diffuse large B-cell lymphoma (MESH:D016403), clear cell renal carcinoma (MESH:D002292), glioblastoma multiforme (MESH:D005909), bladder cancer (MESH:D001749), nasopharyngeal carcinoma (MESH:D000077274)
- **Chemicals:** methionine (MESH:D008715), GTP (MESH:D006160), MgCl2 (MESH:D015636), sodium deoxycholate (MESH:D003840), NaCl (MESH:D012965), methanol (MESH:D000432), FA (MESH:C030544), DEPC (MESH:D004047), digitonin (MESH:D004072), NP-40 (MESH:C010615), BrdU (MESH:D001973), nitrogen (MESH:D009584), bromophenol blue (MESH:D001978), PEI (MESH:D011094), EDTA (MESH:D004492), Triton X-100 (MESH:D017830), ACN (MESH:C032159), polyacrylamide (MESH:C016679), streptomycin (MESH:D013307), H2O (MESH:D014867), phenol (MESH:D019800), XCT790 (MESH:C488234), Peptides (MESH:D010455), iodoacetamide (MESH:D007460), CaCl2 (MESH:D002122), DTT (MESH:D004229), SDS (MESH:D012967), acetic acid (MESH:D019342), ethanol (MESH:D000431), glycine (MESH:D005998), sarkosyl (MESH:C025231), 5xTTBL (-), crystal violet (MESH:D005840), Etop (MESH:C061400), HEPES (MESH:D006531), glycerol (MESH:D005990), penicillin (MESH:D010406), CTP (MESH:D003570), urea (MESH:D014508), etoposide (MESH:D005047), ammonium bicarbonate (MESH:C027043), ATP (MESH:D000255), CO2 (MESH:D002245), cysteine (MESH:D003545), polybrene (MESH:D006583), chloroform (MESH:D002725), agarose (MESH:D012685), KOH (MESH:C029943), Tween-20 (MESH:D011136), PBS (MESH:D007854), KCl (MESH:D011189), spermidine (MESH:D013095), PVDF (MESH:C024865), DAPI (MESH:C007293), Formaldehyde (MESH:D005557), poly(A) (MESH:D011061)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Mutations:** H514A, arginine/lysine
- **Cell lines:** -1 — Mus musculus (Mouse), Hybridoma (CVCL_C7RB), HEK293T — Homo sapiens (Human), Transformed cell line (CVCL_0063), shKDM5C. — Homo sapiens (Human), Chronic myelogenous leukemia, BCR-ABL1 positive, Cancer cell line (CVCL_SU47), S2C — Canis lupus familiaris (Dog), Canine mastocytoma, Cancer cell line (CVCL_1R44), MCF7 — Homo sapiens (Human), Invasive breast carcinoma of no special type, Cancer cell line (CVCL_0031), HCC1937 — Homo sapiens (Human), Breast ductal carcinoma, Cancer cell line (CVCL_0290), MDA-MB-231 — Homo sapiens (Human), Breast adenocarcinoma, Cancer cell line (CVCL_0062), 4T1 — Mus musculus (Mouse), Malignant neoplasms of the mouse mammary gland, Cancer cell line (CVCL_0125), -2 — Homo sapiens (Human), Colon carcinoma, Cancer cell line (CVCL_A628), 4P — Drosophila melanogaster (Fruit fly), Spontaneously immortalized cell line (CVCL_Z998), 6P-R — Mus musculus (Mouse), Hybridoma (CVCL_G242)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12920621/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12920621/full.md

## References

2 references — full list in the complete paper: https://tomesphere.com/paper/PMC12920621/full.md

---
Source: https://tomesphere.com/paper/PMC12920621